These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Role of the new molecules in antiretroviral therapy. Position of raltegravir]. Arribas JR Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427 [TBL] [Abstract][Full Text] [Related]
3. 9th National Retrovirus Conference: new treatments, new choices. Laurence J AIDS Patient Care STDS; 2002 May; 16(5):193-5. PubMed ID: 12055025 [No Abstract] [Full Text] [Related]
4. HIV entry and fusion inhibitors. Chantry D Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132 [TBL] [Abstract][Full Text] [Related]
5. Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy. Wilkin TJ; Taylor B; Olender S; Hammer SM Top HIV Med; 2008; 16(1):31-60. PubMed ID: 18441381 [TBL] [Abstract][Full Text] [Related]
6. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. Hughes A; Barber T; Nelson M J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070 [TBL] [Abstract][Full Text] [Related]
7. Drugs in development. AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058698 [No Abstract] [Full Text] [Related]
8. HIV entry inhibitors. Esté JA; Telenti A Lancet; 2007 Jul; 370(9581):81-8. PubMed ID: 17617275 [TBL] [Abstract][Full Text] [Related]
9. HIV entry inhibitors: progress in development and application. Lai WH; Huang L; Chen CH Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414 [TBL] [Abstract][Full Text] [Related]
11. HIV fusion and its inhibition. LaBranche CC; Galasso G; Moore JP; Bolognesi DP; Hirsch MS; Hammer SM Antiviral Res; 2001 May; 50(2):95-115. PubMed ID: 11369431 [No Abstract] [Full Text] [Related]
12. Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. Loutfy M; Ribera E; Florence E; De Wit S; Castagna A; Ryan R; Hill A; Vanaken H; van Delft Y; Marks S J Antimicrob Chemother; 2009 Dec; 64(6):1341-4. PubMed ID: 19828488 [No Abstract] [Full Text] [Related]
13. HIV Pathogenesis and Treatment - Third International AIDS Society Conference. Susman E IDrugs; 2005 Oct; 8(10):813-5. PubMed ID: 16254799 [No Abstract] [Full Text] [Related]
14. New developments in anti-HIV chemotherapy. De Clercq E Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468 [TBL] [Abstract][Full Text] [Related]
15. Increasing number of anti-HIV drugs but no definite cure. Review of anti-HIV drugs. Stolk LM; Lüers JF Pharm World Sci; 2004 Jun; 26(3):133-6. PubMed ID: 15230359 [TBL] [Abstract][Full Text] [Related]
16. The clinical pharmacology of antiretrovirals in development. Winston A; Mallon PW; Boffito M Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):447-58. PubMed ID: 16863445 [TBL] [Abstract][Full Text] [Related]
17. Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals. Youle M; Cohen C; Katlama C; Kuritzkes D; Walmsley S Lancet; 2004 Sep 18-24; 364(9439):1036-7. PubMed ID: 15380959 [No Abstract] [Full Text] [Related]
18. [Progress in antiretroviral drugs]. Sugiura W Uirusu; 2005 Jun; 55(1):85-94. PubMed ID: 16308534 [TBL] [Abstract][Full Text] [Related]
19. [FDA approved the first of a new class of antiretrovirals for adults and children with advanced HIV infection]. Rev Panam Salud Publica; 2003 Jul; 14(1):57-8. PubMed ID: 12952609 [No Abstract] [Full Text] [Related]
20. Anti-HIV therapy: Current and future directions. Agrawal L; Lu X; Jin Q; Alkhatib G Curr Pharm Des; 2006; 12(16):2031-55. PubMed ID: 16787246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]